Publication: Kidney replacement therapy patients with COVID-19 in the vaccine era: what do we need to know?
dc.contributor.kuauthor | Vehbi, Sezan | |
dc.contributor.kuauthor | Yıldız, Abdullah Burak | |
dc.contributor.kuauthor | Kanbay, Mehmet | |
dc.contributor.kuprofile | Faculty Member | |
dc.contributor.schoolcollegeinstitute | School of Medicine | |
dc.contributor.yokid | N/A | |
dc.contributor.yokid | N/A | |
dc.contributor.yokid | 110580 | |
dc.date.accessioned | 2024-11-09T13:19:36Z | |
dc.date.issued | 2022 | |
dc.description.abstract | Kidney disease is one of the most important factors affecting the prognosis of patients with coronavirus disease 2019 (COVID-19). Patients on kidney replacement therapy (KRT; dialysis and kidney transplant recipients) are vulnerable to severe complications of COVID-19. As the pandemic evolves and preventive strategies, availability of healthcare facilities, treatment approaches and vaccination strategies change, studies are needed on COVID-19 epidemiology and outcomes in KRT patients that contribute to vaccination regimens, treatment protocols and immunosuppressive therapies of KRT patients with COVID-19. In their registry-based study, Quiroga et al. analyzed COVID-19 KRT patients in Spain across six pandemic waves in order to evaluate dynamic treatment approaches and outcomes as well as the efficacy of vaccination. | |
dc.description.fulltext | YES | |
dc.description.indexedby | WoS | |
dc.description.indexedby | Scopus | |
dc.description.indexedby | PubMed | |
dc.description.issue | 9 | |
dc.description.openaccess | YES | |
dc.description.publisherscope | International | |
dc.description.sponsoredbyTubitakEu | N/A | |
dc.description.sponsorship | N/A | |
dc.description.volume | 15 | |
dc.format | ||
dc.identifier.doi | 10.1093/ckj/sfac122 | |
dc.identifier.eissn | 2048-8513 | |
dc.identifier.embargo | NO | |
dc.identifier.filenameinventoryno | IR03745 | |
dc.identifier.issn | 2048-8505 | |
dc.identifier.link | https://doi.org/10.1093/ckj/sfac122 | |
dc.identifier.quartile | Q1 | |
dc.identifier.scopus | 2-s2.0-85141287925 | |
dc.identifier.uri | https://hdl.handle.net/20.500.14288/3137 | |
dc.identifier.wos | 824737900001 | |
dc.keywords | COVID-19 | |
dc.keywords | Dialysis | |
dc.keywords | Immunosuppression | |
dc.keywords | Kidney replacement therapy | |
dc.keywords | SARS-Cov-2 vaccination | |
dc.language | English | |
dc.publisher | Oxford University Press (OUP) | |
dc.relation.grantno | NA | |
dc.relation.uri | http://cdm21054.contentdm.oclc.org/cdm/ref/collection/IR/id/10606 | |
dc.source | Clinical Kidney Journal | |
dc.subject | Urology and nephrology | |
dc.title | Kidney replacement therapy patients with COVID-19 in the vaccine era: what do we need to know? | |
dc.type | Other | |
dc.type.other | Editorial material | |
dspace.entity.type | Publication | |
local.contributor.authorid | N/A | |
local.contributor.authorid | N/A | |
local.contributor.authorid | 0000-0002-1297-0675 | |
local.contributor.kuauthor | Vehbi, Sezan | |
local.contributor.kuauthor | Yıldız, Abdullah Burak | |
local.contributor.kuauthor | Kanbay, Mehmet |
Files
Original bundle
1 - 1 of 1